Investigating antibody molecules for treating human diseases v1.0

  • Research type

    Research Study

  • Full title

    Use of human tissue to investigate novel antibody molecules for treating human diseases

  • IRAS ID

    346726

  • Contact name

    Elizabeth Hardaker

  • Contact email

    liz@epsilogen.com

  • Sponsor organisation

    Epsilogen Ltd

  • Clinicaltrials.gov Identifier

    N/A, N/A

  • Duration of Study in the UK

    5 years, 0 months, 1 days

  • Research summary

    Antibody drugs are commonly used for the treatment of human diseases, such as cancer and autoimmune diseases. At Epsilogen Ltd we are generating novel antibody drugs to treat such diseases. To develop effective antibody drugs, human tissue is required to evaluate their functionality and biological mechanism of action. As such, at Epsilogen Ltd we require human tissue to perform in vitro experiments to assess pre-clinical antibody drug candidates for complete compound evaluation.

  • REC name

    London - South East Research Ethics Committee

  • REC reference

    24/PR/0880

  • Date of REC Opinion

    22 Jul 2024

  • REC opinion

    Favourable Opinion